AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Status:
Unknown status
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner.
Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done
with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone
in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine.
Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA
is performed.